3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
4
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
14
Plasma cell
11
Lymphoid
11
Sarcoma
4
Gynecologic
4
Myeloid
3
Gastrointestinal
3
Dermatologic
3
CNS
2
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Endocrine
1
Breast
1
Conditions
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
463
Cisplatin
379
Paclitaxel
313
Pemetrexed
300
Docetaxel
242
Erlotinib Hydrochloride
240
Gemcitabine
232
pembrolizumab
173
Radiotherapy
172
Bevacizumab
169
Nivolumab
130
Etoposide
106
Gefitinib
95
Vinorelbine
84
durvalumab
71
atezolizumab
68
Cetuximab
65
Topotecan
61
Drug Therapy
57
Ipilimumab
55
Irinotecan
54
osimertinib
53
Radiosurgery
52
Afatinib
51
Surveys and Questionnaires
38
130-nm albumin-bound paclitaxel
38
Albumin-Bound Paclitaxel
37
Taxes
35
Cyclophosphamide
35
Surgical Procedures, Operative
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
selinexor
×
Thoracic
×
Clear all
NCT04256707
2025-03-19
SPRINT
Karyopharm Therapeutics Inc
Phase 1/2
Completed
126 enrolled